Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Next Previous
X
Search
Trial Profile

A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efbemalenograstim alfa (Primary)
  • Indications Chemotherapy induced febrile neutropenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Evive Biotech

    • Most Recent Events

    • 16 Dec 2023 Results reporting safety and efficacy data published in the Supportive Care in Cancer
    • 07 Jul 2020 According to an Evive Biotech media release, the company progresses its BLA submission with the FDA and equivalent submissions around the world.
    • 24 Jan 2018 According to a Generon Corporation media release, This is one of two pivotal Phase III studies required for BLA submission in the US.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top